• Bulletin of the Korean Chemical Society
• /
• 제33권12호
• /
• pp.4255-4257
• /
• 2012

• Bulletin of the Korean Chemical Society
• /
• 제24권9호
• /
• pp.1365-1367
• /
• 2003

• Bulletin of the Korean Chemical Society
• /
• 제32권8호
• /
• pp.2689-2694
• /
• 2011

Novel 5'-norcarbocyclic adenine and guanine phosphonic acid analogues with 6'-electronegative moiety such as unsaturated C-C bond were designed and synthesized from commercially available 2-methylene-propane-1,3-diol (4). Regioselective Mitsunobu reaction successfully proceeded from an allylic functional group (${\pm}$)-12b at low reaction temperature in polar cosolvent (DMF/1,4-dioxane) to give purine phosphonate analogues (${\pm}$)-13 and (${\pm}$)-20. The purine nucleoside phosphonate and phosphonic acid analogues were subjected to antiviral screening against HIV-1. Guanine analogue (${\pm}$)-23 shows significant anti-HIV activity in PBM cell lines ($EC_{50}=8.1\;{\mu}M$).

• Bulletin of the Korean Chemical Society
• /
• 제29권5호
• /
• pp.993-997
• /
• 2008

Two directional ring-closing metathesis (RCM) was applied successfully to the synthesis of 4'-vinylated carbocyclic nucleoside analogues from the trivinyl intermediate 12, which was readily made using a sequential Claisen rearrangement and ring-closing metathesis (RCM) starting from Weinreb amide 5. An antiviral evaluation of the synthesized compounds against various viruses such as HIV, HSV-1, HSV-2 and HCMV revealed that the guanine analogue 20 have moderate anti-HIV activity in the MT-4 cell line ($EC_{50}$ = 10.2 $\mu$ M).

• Bulletin of the Korean Chemical Society
• /
• 제29권9호
• /
• pp.1723-1728
• /
• 2008

An efficient synthetic route for carbocyclic versions of stavudine analogues and their evaluation on antiviral activity are described. The construction of an ethynylated quaternary carbon at the 4'-position of carbocyclic nucleosides was accomplished using Claisen rearrangement of 11 and ring-closing metathesis (RCM) of dienyne 14 as key transformations. An antiviral evaluation of the synthesized compounds, 20, 21, 22, and 25 against HIV-1, HSV-1, HSV-2, and HCMV showed that only the guanine analogue 25 is moderately active against HIV-1 in the MT-4 cell line ($EC_{50}$ = 11.91 $\mu$mol).

• Journal of Radiation Protection and Research
• /
• 제22권1호
• /
• pp.15-21
• /
• 1997

인체 T-림프구에서 감마선과 대표적 화학 독성물질인 pentachlorophenol(PCP)의 돌연변이 효과를 hypoxanthine phosphoribosyl transferase(hprt) 유전자의 돌연변이 빈도로써 측정하였다. 감마선은 $^{137}$Cs원을 사용하여 세포의 초기배양 시기에 0-3.0 Gy를 조사하였고, PCP는 세포의 초기배양시 최종농도 0-100 ppm으로 24시간 투여하였다. 돌연변이세포는 6-thioguanine을 처리 하에 세포가 성장하는 능력으로 분류하였다. 방사선에 의한 돌연변이빈도는 1.0 Gy, 2.0 Gy와 3.0 Gy 선량에서 대조군보다 약40%, 400%와 750% 증가하였고 0.2 Gy와 0.5 Gy의 선량에서는 유의성 있는 변화가 없었다. PCP를 15 ppm, 25 ppm 그리고 50 ppm을 처리하였을 때 대조군보다 각각 30%, 90% 및 520%정도 증가하였다.

• Journal of Pharmaceutical Investigation
• /
• 제38권3호
• /
• pp.199-205
• /
• 2008

Famciclovir, 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine, is an oral prodrug of the antiherpesvirus nucleoside analogue, penciclovir. In human, famciclovir is orally well absorbed and then undergoes extensive first pass metabolism to penciclovir and essentially no parent compound is recovered from plasma or urine. The purpose of the present study was to evaluate the bioequivalence of two famciclovir tablets, Famvir tablet 750 mg (Novartis Korea Ltd.) and Famcivir tablet 750 mg (Hanmi Pharmaceutical. Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The release of famciclovir from the two famciclovir formulations in vitro was tested using KP VIII Apparatus II method with water. Twenty six healthy male subjects, $23.38{\pm}1.72$ years in age and $68.59{\pm}7.84\;kg$ in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After a single tablet containing 750 mg as famciclovir was orally administered, blood samples were taken at predetermined time intervals and the concentrations of penciclovir in serum were determined using HPLC with UV detector. The dissolution profiles of two formulations ere similar at water. The pharmacokinetic parameters such as $AUC_t$, $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$, $C_{max}$ and untransformed $T_{max}$. The results showed that the differences between two formulations based on the reference drug, $Famvir^{(R)}$ tablet 750 mg, were -0.53%, 1.12% and -24.82% for $AUC_t$, $C_{max}$ and $T_{max}$, respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log 0.8 to log 1.25 (e.g., $log\;0.9569{\sim}log\;1.0423$ and $log\;0.8763{\sim}log\;1.2136$ for $AUC_t$ and $C_{max}$, respectively). Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Famcivir tablet 750 mg was bioequivalent to Famvir tablet 750 mg.

• Journal of Yeungnam Medical Science
• /
• 제25권1호
• /
• pp.31-40
• /
• 2008

충북대학교 병원과 영남대학교 병원에서 만성 B형 간염으로 내원한 환자를 대상으로 9개월 동안 엔테카비어를 투약한 뒤 그 치료성적을 조사하여 본 결과 외국 연구의 성적과 유사하게 생화학적 반응에서 3개월째는 20명(61%), 6개월째는 24명 (73%), 9개월째는 22명(67%), 바이러스학적 반응에서 3개월째 바이러스학적 반응은 27명 (82%), 6개월째는 30명 (91%), 9개월째는 30명 (91%), 바이러스 비검출율에서 3개월째는 16명 (49%), 6개월째는 24명 (73%), 9개월째는 28명 (85%)로 우수한 치료성적을 보여주었다. 치료 9개월째 바이러스 돌파현상은 2명에서 관찰되었다. 결론적으로 엔테카비어는 만성 B형 간염 환자에서 이전의 다른 뉴클레오사이드 유도체보다 좋은 치료효과 및 낮은 내성 발현율을 보이고 있다.